Key points are not available for this paper at this time.
Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
John F. Seymour
Thomas J. Kipps
Barbara Eichhorst
New England Journal of Medicine
University of California, San Diego
Memorial Sloan Kettering Cancer Center
The University of Melbourne
Building similarity graph...
Analyzing shared references across papers
Loading...
Seymour et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69936e1f53522ac2836263e8 — DOI: https://doi.org/10.1056/nejmoa1713976